Sarepta Therapeutics (NASDAQ:SRPT) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
Valuation & Earnings
This table compares Sarepta Therapeutics and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Sarepta Therapeutics | $380.83 million | 18.04 | $-715,080,000.00 | ($9.71) | -8.97 |
| Revance Therapeutics | $410,000.00 | 4,262.38 | $-159,430,000.00 | ($3.67) | -7.16 |
Revance Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
89.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Sarepta Therapeutics and Revance Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Sarepta Therapeutics | -121.30% | -61.62% | -23.02% |
| Revance Therapeutics | -5,818.87% | -85.72% | -44.85% |
Risk and Volatility
Sarepta Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Sarepta Therapeutics and Revance Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Sarepta Therapeutics | 1 | 8 | 13 | 0 | 2.55 |
| Revance Therapeutics | 0 | 1 | 6 | 0 | 2.86 |
Sarepta Therapeutics currently has a consensus price target of $156.1905, suggesting a potential upside of 79.41%. Revance Therapeutics has a consensus price target of $32.8333, suggesting a potential upside of 25.03%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Revance Therapeutics.
Summary
Sarepta Therapeutics beats Revance Therapeutics on 9 of the 14 factors compared between the two stocks.
